The discovery was made by researchers from the Faculty of Medicine of Sao Jose do Rio Preto (FAMERP), a city in the interior of the state of Sao Paulo (southeast of Brazil) and was published this month in the journal Transplantation Direct.
The FAMERP study was awarded by the Brazilian Association of Organ Transplants and by the International Society of Transplants.
Currently, the kidneys that are used for transplants come from people who had brain death. These organs are classified into two types: kidney of the standard type (good to be transplanted) or kidney different from the standard (also known as kidney of extended criteria). This type of kidneys generally come from donors over 60 years; and in most cases, end up being discarded.
The scientists identified that kidneys different from the standard may have more complications due to inflammation in some of its molecules. These inflammations occur when the organ is stored for donation, due to lack of oxygen or due to the low temperatures at which the kidney is subjected during the process.
“What was not known is that if the inflammation is treated, the kidney is again capable of being transplanted, without causing problems for the recipient. With biopsies that we made in the kidneys of extended criteria, we managed to identify which molecules were affected by the inflammation, which we managed to deactivate or treat them and thus, reduce inflammation of the kidney,” researcher Mario Filho said.
According to Filho, “there are some medications that can act and decrease this inflammatory process before placing the kidney in the recipient’s body, thus decreasing the rate of rejection and of discarding of these kidneys.”
“What we are looking for is a way to improve the quality of the kidney and the recipient. The population [life’s] expectation is growing; and with it, the organs for transplants are getting older, which represents a challenge for science and medicine,” added the specialist.
The next step of the researchers is to ensure the viability of the treatment’s logistics; which will involve ensuring the supply of the medicines where there is a donated kidney.
“Now we will wait for the evaluation of the international criticism on the results of the treatment, and to see if some laboratory helps us to make this process viable,” added Filho.
Source: Agencia ID